Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 5/20 | 0.73 |
| ▸ | CA12 | O43570 | 3/20 | 0.73 |
| ▸ | RPA1 | P27694 | 1/20 | 0.73 |
| ▸ | ACR | P10323 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 10/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 10/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 10/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 10/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 10/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 10/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 10/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 5/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.51 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3447352 | 0.85 | ALPL (1.00) | ALPLCA12RPA1HDAC3HDAC4 | |
| SCHEMBL18726258 | 0.83 | ACR (0.57) | ALPLCA12RPA1ACRTP53 | |
| SCHEMBL13539270 | 0.83 | ALPL (0.73) | ALPLCA12RPA1ACRHDAC3 | |
| SCHEMBL2846632 | 0.83 | ALPL (0.73) | ALPLCA12RPA1ACRTP53 | |
| SCHEMBL29444415 | 0.83 | ALPL (0.73) | ALPLCA12RPA1ACRTP53 | |
| SCHEMBL2789578 | 0.83 | TP53 (0.74) | ALPLCA12RPA1ACRTP53 | |
| SCHEMBL18726294 | 0.83 | SCN9A (0.57) | ALPLCA12RPA1TP53SCN9A | |
| SCHEMBL4789868 | 0.81 | CCNC (0.54) | ALPLCA12RPA1HDAC3HDAC4 | |
| SCHEMBL30147638 | 0.81 | CHEK1 (0.72) | ALPLCA12RPA1ACRHDAC3 | |
| SCHEMBL20661049 | 0.80 | TP53 (0.51) | ALPLCA12RPA1ACRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| CN-114057646-B | Pyrazole derivative and application thereof in preparation of antitumor drugs | 常州大学 | 2023-05-02 | — | — | CN | disclosed |
| CN-115894373-A | N-substituted benzylpyrazole derivatives as beta 2 Use of allosteric modulators, antagonists and agonists of the adrenergic receptor | 常州大学 | 2023-04-04 | — | — | CN | disclosed |
| CN-114057646-A | Pyrazole derivative and application thereof in preparation of antitumor drugs | 常州大学 | 2022-02-18 | — | — | CN | disclosed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | disclosed |
| US-8501756-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2013-08-06 | — | — | US | disclosed |
| US-8367667-B2 | Pyrrole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20130012529-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2013-01-10 | — | — | US | disclosed |
| US-20110301128-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301128-A1 | Pyrrole Derivatives As Pharmaceutical Agents | PRLHR, PTGDR, TACR1 | ALPL 3909/4885CA12 3901/4885RPA1 4279/4885 |
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | PRLHR, PTGDR, TACR1 | ALPL 3909/4885CA12 3901/4885RPA1 4279/4885 |
| US-20130012529-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | CDK2, PHKG1, PHKG2 | ALPL 4698/4885CA12 3536/4885RPA1 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.